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The rapid and efficient clearance of apoptotic cells results in the elimination of auto-antigens
and provides a strong anti-inflammatory and immunosuppressive signal to prevent autoim-
munity. While professional and non-professional phagocytes utilize a wide array of surface
receptors to recognize apoptotic cells, the recognition of phosphatidylserine (PS) on apop-
totic cells by PS receptors on phagocytes is the emblematic signal for efferocytosis in meta-
zoans. PS-dependent efferocytosis is associated with the production of anti-inflammatory
factors such as IL-10 andTGF-β that function, in part, to maintain tolerance to auto-antigens.
In contrast, when apoptotic cells fail to be recognized and processed for degradation, auto-
antigens persist, such as self-nucleic acids, which can trigger immune activation leading to
autoantibody production and autoimmunity. Despite the fact that genetic mouse models
clearly demonstrate that loss of PS receptors can lead to age-dependent auto-immune
diseases reminiscent of systemic lupus erythematosus (SLE), the link between PS and
defective clearance in chronic inflammation and human autoimmunity is not well delin-
eated. In this perspective, we review emerging questions developing in the field that may
be of relevance to SLE and human autoimmunity.
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INTRODUCTION
The clearance of apoptotic cells by phagocytic cells (a process now
called efferocytosis to distinguish the processing of apoptotic cells
from other phagocytic processes) is critically important to main-
tain homeostasis in multicellular organisms. Efficient efferocytosis
not only allows for the removal and degradation of effete and dam-
aged cells, but has an equally important function in the resolution
of inflammation by protecting tissue from harmful exposure to
the inflammatory and immunogenic contents of dying cells (1–4).
There is now considerable genetic evidence supported by mouse
knockout studies that failed or delayed efferocytosis results in the
release of auto-antigens that can contribute to the etiology of auto-
immune diseases such as systemic lupus erythematosus (SLE) (5).
In addition, macrophages derived from SLE patients also exhibit
defects in efferocytosis (6, 7). Elucidating the genetic basis for
defective clearance in relation to human autoimmunity is clearly
a topical and important area of research.
Concomitant with caspase activation and cell death, apoptotic
cells display a wide array of nascent and modified molecular deter-
minants on their plasma membranes that act as “eat-me” signals
for phagocytes. While these determinants result from a combina-
tion of re-localized proteins, modified carbohydrates, and from
collapse of phospholipid asymmetry at the plasma membrane, the
externalization of phosphatidylserine (PS) is arguably the most
emblematic event associated with the early phase of apoptotic
program (8–10). If apoptotic cells escape immediate clearance,
a second wave of late apoptotic cells clearance is mediated by
opsonins that includes nuclear materials (11), C1q (12), ficolins
(13), and pentraxins (14–16). The late apoptotic cells bound by
these opsonins are then recognized and cleared via phagocytic
receptors including FcγRIIA, C1q receptor, CR1, CD91, and cal-
reticulin (CRT), helping to avoid inflammation (17, 18). Although
our discussion here focuses on cross-interactions between differ-
ent PS receptors and opsonins, the crosstalk between different
recognition systems (such as PS and modified carbohydrates and
PS and protein neoepitopes) is likely equally important.
The fact that blockage of PS on the apoptotic cell prevents
many of the anti-inflammatory consequences of efferocytosis,
combined with observations that knockout of several PS receptors
and PS opsonins (soluble factors that link PS on apoptotic cells to
receptors) lead to failed efferocytosis, chronic inflammation, and
age-dependent autoimmunity (4) has led many investigators to a
conceptual framework that externalized PS functions as a damp-
ening platform for negative immune regulation. In this capacity,
externalized PS functions both as an “eat-me” signal for efferocy-
tosis, but also as an “inflammo-suppression” signal that promotes
tolerance for both immune cells and non-immune bystander cells
that come in direct contact with PS externalized membranes (2, 19,
20). Despite convincing evidence as gleaned from knockout stud-
ies in mouse, identifying links between defective PS recognition
and/or signaling and human autoimmunity has been surprisingly
enigmatic (Table 1).
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Table 1 | Summary of PS receptors and soluble PS binding proteins and their relationship to autoimmunity in mouse and human systems.
Molecule Function Mouse Human
PS BRIDGING MOLECULES
GAS-6 Bridging molecule between PS and TAM
receptor
Deficiency causes platelet dysfunction and
protects against thrombosis (21)
Polymorphism positively
associated with cutaneous
vasculitis in SLE patients (22)
Protein S Bridging molecule between PS and TAM
receptors
Knockout is embryonic lethal (23) SLE patients have reduced level
of circulating protein S (24, 25)
MGF-E8 Bridging molecule between PS and
αvβ3/β5 integrins
Deficient mice develops auto-immune disease (26) Polymorphisms and aberrant
splicing reported in some SLE
patients (27, 28)
C1q Acts as PS bridging molecule to SCARF1
and CD91/LRP1. C1q also binds annexin
A2, A5, and CRT
Deficiency leads to auto-immune diseases (29) Ninety percent of C1q-deficient
individuals develop SLE (30)
MBL Bridging molecule between PS and
CD91/LRP1
Deficiency leads to defective clearance of
apoptotic cells but no auto-immune phenotype (31)
Polymorphisms are SLE risk
factors (32, 33)
High molecular
weight kininogen
Bridging molecule between PS and uPAR NR NR
Thrombospondin Bridging molecule between PS and CD36 NR NR
CRT Binds to PS in a complex with C1q Knockout is embryonic lethal (34) NR
PS RECEPTORS
TAM receptors Indirectly recognize PS via protein S or
GAS-6
Tyro-3KO/AxlKO/MerKO triple knockout mice develop
auto-immune diseases (35). MerKO single knockout
mice develop progressive SLE-like autoimmunity
(36)
Polymorphisms in Mer gene
associated with multiple
sclerosis susceptibility (37).
Increased sMertk in advanced
atheromata (38) and SLE (39)
Tim-4 Directly recognize PS Administration of anti-Tim4 mAb into mice caused
auto-antibodies production (40)
NR
CD300f Directly recognize PS Deficient mice develop a SLE-like disease (41) NR
SCARF1 Indirectly recognize PS via binding to C1q Deficient mice developed SLE-like disease (42) NR
Stabilin-1/2 Directly recognize PS Deficient mice do not show any SLE-related
phenotype (43)
NR
BAI-1 Directly recognize PS NR NR
RAGE Directly recognize PS Deficiency causes impaired phagocytosis but no
SLE-related phenotype (44)
Polymorphism associated with
SLE and disease severity in
lupus nephritis (45)
CD91/LRP1 Indirectly recognize PS via binding to C1q
and/or collectins (MBL, SP-A, SP-D)
Deficient mice are embryonic lethal (46) SLE patients have significantly
increased levels of circulating
soluble CD91/LRP1 (47)
NR, not reported.
MICE LACKING PS RECEPTORS ARE PRONE TO LUPUS-LIKE
AUTO-IMMUNE CONDITIONS
Over the past decade, a diverse array of PS receptors and solu-
ble PS bridging proteins that link apoptotic cells to phagocytes
have been identified (48–50) (Table 1). Although this suggests
significant redundancy at the biochemical level, PS receptors do
not appear to act in a compensatory capacity by loss-of-function.
For example, on certain genetic backgrounds, single knockouts of
Mer (36), Tim-1 (51), Tim-4 (40), SCARF1 (42), and CD300f (41)
all have a common phenotype that include defective apoptotic cell
clearance, the subsequent production of auto-antibodies, and SLE-
like autoimmunity. Similarly, a knockout of MFG-E8 (26), a PS
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opsonin that bridges apoptotic cells toαvβ5 andαvβ3 integrin, also
produces a strong SLE-like phenotype. While in some cases dual
targeting of PS receptors can compound phenotypic outcomes
[for example Tim-4 and MFG-E8 (52) develop autoimmunity at
an earlier age, or triple knockout of TAM (Tyro3, Axl, and Mer)
(35) have a more potent onset of disease than Mer alone), collec-
tively these data suggest, at least in the mouse, that PS receptors
are not functionally redundant. One possible interpretation is that
PS receptors, analogously to the immunological synapse for T cell
signaling, comprise a multi-protein signaling receptor complex,
perhaps akin to a PS phagocytic synapse, where loss-of-function
of any single component disrupts the higher order functional unit
(53, 54). Several of the known PS receptors, such as αvβ5 integrin
and Mertk, are known to synergize in order to activate intracellular
signaling pathways such as Rac1 (55, 56) also supporting the idea
of receptor crosstalk. However, while attractive to speculate, such
a multi-protein structure (aka, the “engulfosome”) has not been
identified at a biochemical level.
Clearly then, an obvious question is whether the aforemen-
tioned PS circuitry fails, or is a genetic risk factor for human
auto-immune disease such as SLE. Presently, the answer is still
not clear, although of the major PS recognition receptors that give
rise to autoimmunity in mice (Mer, Tim-1, Tim-4, SCARF1, and
CD300f), their involvement in human autoimmunity is not yet
obvious from genetic linkage analysis. Although MFG-E8 muta-
tions have been identified in a small subset of lupus patients
(28), and a case-control study of MFG-E8 genetic polymorphisms
showed some genetic linkage (27), these events appear to be rare.
Likewise in the case of TAMs (Mer) and their ligands, it was shown
that in SLE patients, TAM levels do not appear to be compromised
(57, 58), and in some patients, serum levels of Mer and TAM
ligands actually appear to be elevated (59–61).
The recent studies by Ramirez-Ortiz and colleagues, identifying
the scavenger receptor SCARF1 (SREC1, CED-1) as a PS receptor
that recognizes a PS in the context of complement component C1q
(42) might have relevance to human SLE. In vivo, SCARF1 (−/−)
mice in develop systemic SLE-like disease, including the generation
of auto-antibodies and glomerulonephritis that closely mimics
human SLE (42). Interestingly, while SCARF1 was shown to bind
via PS, apoptotic cells deficient in C1q were notably impaired in
their ability to bind to and activate SCARF1, suggesting the C1q
acts as a requisite bridging molecule for PS. In addition to SCARF1,
C1q also binds to PS-opsonized CRT (62) on the surface of apop-
totic cells (a ligand for CD91/LRP1 on the phagocyte), as well as
other PS-binding proteins that include Annexin A5 and Annexin
A2 (63). Although genetic deficiency of C1q is quite rare (<100
known cases have been reported), over 90% of these individu-
als develop SLE (30), and monocytes (64, 65) derived from these
patients have impaired ability to clear apoptotic cells suggesting a
defect in the apoptotic cell clearance machinery. In addition, apop-
totic cells derived from SLE patients also show greatly diminished
capacity to bind C1q (66) suggesting one or more of the deter-
minants on the apoptotic cell that bind C1q is also deficient in
SLE. Although monocytes isolated from SLE patients showed only
a modest decrease in CD91/LRP1 levels, patients with rheuma-
toid arthritis or SLE showed significantly elevated levels of soluble
CD91/LRP1 cleaved by ADAM17 in response to inflammation
(47). Possibly related, excessive protease cleavage of Mertk from
macrophages has also been linked to inefficient clearance in the
development of advanced atheromata (38) and SLE (39). Clearly,
it will be of interest to ascertain at the genetic level whether loss-of-
function mutations occur at CD91/LRP1 or SCARF1 receptor loci
that result in risk associations for human auto-immune diseases.
Taken together, while loss-of-function genetic ablation studies
in mouse models clearly show a link between systemic autoimmu-
nity and loss-of-function of PS receptors, translating this biology
into human SLE pathology still remains somewhat of a mys-
tery. Future studies should address whether PS receptor biology
is arranged differently in humans in comparison to mice PS recep-
tors, allowing for more redundancy, or whether defective PS signal-
ing in human is part of a multi-genic signature that acts as a cohort
with other risk factors. Another caveat on relying on expression
analysis is that many SLE and auto-immune patients are chroni-
cally treated with glucocorticoids and steroids, which may affect
the levels of PS receptors or PS-opsonins. For example, Lauber
and colleagues showed that MFG-E8 is transcriptionally regulated
by dexamethasone, a steroid used to treat the chronic inflamma-
tion associated with lupus (67). In addition to MFG-E8, the TAM
receptors are also subject to acute regulation by glucocorticoids
but in a reciprocal fashion; Mer is up-regulated while Axl is down-
regulated following dexamethasone treatment (68). This could
also induce a feed-forward mechanism, where dexamethasone-
induced increase in Mer levels could increase efferocytosis, which
itself further increases Mer by the increased uptake of apoptotic
cargo. Internalized apoptotic cells increase ingested cholesterol,
which can activate LXR and activate the Mer promoter (69, 70).
This idea that corticosteroids mediate their effects by manipulat-
ing PS biology might be interrogated via the development of more
specific therapeutics for SLE.
Another possible reason for the discrepancy between the stud-
ies in mice and the observations in human autoimmunity is that
defects in PSR signaling (generated in mouse models) may not be
manifested as defects in PSRs or PS-opsonins in human autoim-
munity but by mutations in genes involved in the mechanisms
upstream such as PS externalization or modification. We explore
facets of this hypothesis in the following three sections.
SCRAMBLASES, FLIPPASES, AND UPSTREAMMECHANISMS
OF PS EXPOSURE
While the past decade has shown great strides in elucidating the
repertoire of PS receptors that bind to and rely signals from PS on
the apoptotic cell to phagocytic receptors, in recent years, there has
also been a much greater appreciation for the genes and regulatory
circuits that control PS externalization, including the realization
that mutations in these genes can lead to pathologies related to dys-
functional PS biology. Novel scramblases and flippases responsible
for PS externalization have been enumerated, opening up the pos-
sibility that genes that control externalization, and defects therein,
may also contribute to chronic inflammation and autoimmunity.
Similar to other lipids, PS is synthesized in the endoplasmic
reticulum and golgi apparatus and then transported to the plasma
membrane by carrier proteins. Once PS reaches the plasma mem-
brane, it is actively excluded from the extracellular milieu by
several complementary enzymes. These enzymes, in part, maintain
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membrane asymmetry, with the choline-containing phospho-
lipids; PC and SM predominantly maintained in the outer leaflet,
and the amino-phospholipids; PS, PE, and PI predominately on
the inner leaflet (71). To maintain PS asymmetry under homeosta-
tic conditions, three main types of enzymes operate at equilibrium,
but each can be perturbed during apoptosis and during cell stress.
Flippases and Floppases translocate phospholipids from the outer
surface to the inner surface and from the inner surface to the outer
surface, respectively, and both require ATP for this activity (72).
A third, and least understood class of lipid transporters that regu-
late PS topology are called scramblases, and as their name implies,
when activated, collapse membrane asymmetry, and in the context
of PS biology, promote the accumulation of PS to the external side
of the membrane.
Although phospholipid scramblases do not show selectivity for
the phospholipid species or for the direction of movement, the
scramblase-mediated exposure of PS has important consequences
for several biological events that include coagulation, neurotrans-
mitter release, sperm capacitation, and apoptosis (73). While PS is
externalized during both platelet activation and during apoptosis,
the recent characterization of two scramblases, Transmembrane
protein 16F (TMEM16F) (74, 75) and Xkr8 (76), provide some
conceptual relief to this field, highlighting that cells externalize
PS through different activation and regulatory mechanisms, but
of equal significance, that not all externalized PS has the same
biological function.
Transmembrane protein 16F is an eight-transmembrane span-
ning aminophospholipid scramblase that is critical for the
calcium-dependent externalization of PS in activated platelets.
In the studies from Nagata and colleagues, these investigators
developed a clever FACS sorting approach to characterize a Ba/F3
pro-B cell sub-line that can be trained to respond to sub-threshold
concentrations of calcium. After repetitive sorting of PS-positive
cells, a Ba/F3 sub-clone that contained a mutated TMEM16F and
constitutively scrambled PS was identified (74). Further stud-
ies showed that loss of TMEM16F function, either via knockout
or through mutation, impairs calcium-dependent PS scramblase
activity, and when occurring in platelets, results in their inability
to recruit and activate hemostasis factors that include factor V,
factor X, and prothrombin to the platelet membrane (75). DNA
sequence analysis further showed that Scott syndrome patients,
which are characterized by a rare bleeding disorder that have
defects on calcium-dependent phospholipid scrambling, carry
loss-of-function mutations in both Tmem16 alleles. Functionally,
other members of TMEM16 family, including 16C, 16D, 16F, 16G,
and 16J are also capable of scrambling PS, but further studies
will be required to ascertain whether different family members are
specific for different cell types (77).
Notably, the above-mentioned Ca2+-stimulated PS externaliza-
tion induced by TMEM16F is readily reversible upon restoration
of Ca2+ homeostasis, while the PS externalized during caspase-
mediated apoptosis is distinct and separable from TMEM16F,as PS
externalization is maintained in apoptotic TMEM16F (−/−) cells
treated with Fas-L to induce apoptosis (77). Remarkably, when a
mutant TMEM16F was introduced into a mouse lymphoma cell
(W3-Ildm) to achieve constitutive PS exposure, these PS-positive
tumor cells were not targets of efferocytosis, even by professional
DCs, and only became phagocytic competent after treatment with
Fas-L to activate caspase 3 (78). These data offer a molecular expla-
nation as to why activated cells, such as during platelet aggregation,
T cell activation, and during mast cell degranulation, externalize
PS but fail to be engulfed. Conceptually, these data suggest that PS
externalization, per se, while necessary, is not sufficient to promote
clearance (Figure 1).
FIGURE 1 | Different modes of PS externalization by lipid scramblases.
Under basal resting conditions, the amino-phospholipids (PE and PS) are
restricted to the inner surface of the plasma membrane (A). During
conditions of cell stress or platelet activation (B) or during apoptosis (C),
membrane asymmetry is lost and PS is externalized to the extrafacial
surface (depicted in red). Under basal conditions (A), plasma membrane
asymmetry is maintained by the combined activity of cellular flippases and
floppases. During cell stress or during platelet activation, intracellular
calcium levels rise, resulting in the activation of TMEM16F, and PS exposure
to the extracellular leaflet (B). During apoptosis and the activation of
caspases, executioner caspases are able to cleave and activate Xkr8, as
well as cleave and inactivate ATP11C, resulting in PS exposure to the
extracellular leaflet. Since PS externalized PS via TMEM16F and
Xkr8/ATP11C are differentially recognized as eat-me signals, it is likely that
the density of PS, or the oxidation state of the PS, provide assurance
signals for efferocytosis. Key: PE, phosphatidylethanolamine; PC,
phosphatidylcholine; PI, phosphatidylinositol; PS, phosphatidylserine;
Oxidized PS, oxidized phosphatidylserine.
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To identify scramblases associated with apoptosis, Nagata and
colleagues used expression cloning to identify scramblases strictly
dependent on caspase activity (i.e., inhibited by zFAD-fmk but
not dependent on calcium). Based on these screens, a novel
scramblase called Xkr8 was identified. Analogous to TMEM16F,
over-expression of Xkr8 significantly increased PS exposure, but
in stark contrast to TMEM16F, Xkr8 cells that express PS were
recognized as an eat-me signal and engulfed. At the molecular
level, Xkr8 is cleaved at a DEVD site near its C-termini by cas-
pase 3 and caspase 7 during apoptosis, to activate a PS scramblase
activity (76). Xkr8 is a mammalian homolog of the CED8 in
Caenorhabditis elegans (79) and has an evolutionarily conserved
function and is cleaved by CED-3, the homolog of caspase 3,during
developmental apoptosis.
Adding complexity to the issue of PS externalization during
apoptosis, new studies indicate that a net accumulation of exter-
nalized PS is also achieved by a dynamic and systematic interplay
between PS scramblases (such as Xkr8) and specific flippases,
such as ATP11C (a member of the P4-type ATPase family that
redirects PS from the outer membrane back to the inner mem-
brane) (80). Analogous to Xkr8, ATP11C also contains a caspase
cleavage site, but when ATP11C is cleaved by active caspases, the
Flippase activity is inactivated preventing the return of PS to
the inner membrane. Interestingly, when cells express ATP11C
with a mutated caspase recognition site, cellular flippase activity
remains high, and cells expressing mutant ATP11C do not sus-
tain PS externalization or retain their ability to be engulfed. This
presents a highly intricate scenario, whereby caspases can activate
Xkr8 and inactivate ATP11C, to increase the steady-state density
of externalized PS (Figure 1). In contrast, in the non-apoptotic
context, high concentration of calcium activates TMEM16, but
does not inactivate ATP11C, possibly explaining the reversibility
of TMEM16-mediated PS externalization.
Using an LC MS/MS labeling approach to derivatize primary
amines on externalized amino-phospholipids (PE and PS), recent
studies by Clark et al. found that different molecular species of
amino-phospholipids (according to their fatty acyl composition,
saturation, length,and oxidative status) were simultaneously exter-
nalized during platelet activation versus apoptosis, and revealed an
optimal PE fatty acyl chain length that supported coagulation (81).
Similar types of MS-based characterization have been reported
to define the molecular species of oxidized PS (oxPS) driven by
cytochrome c/H202 (82). These kinds of analyses might be reveal-
ing to accesses changes in the PS lipidome in SLE patients, or which
species of PS are targets of anti-PS or anti-phospholipid anti-
bodies in SLE. Moreover, the recent development of PS reporter
lines, such as the generation of chimeric reporter cells to study
the PS-dependent dimerization and activation of TAM recep-
tors (Tyro3-γR1, Axl-γR1, and Mer-γR1 cells) (83), or the use
of SCARF1 chimeric receptors to access the contribution of PS to
C1q signaling (42), would be very useful to explore the functional
analysis for PS receptors and to screen apoptotic cells from differ-
ent cells undergoing apoptosis (normal versus SLE patients). By
expanding this kind of analysis, it might be possible to identify if
(and how) PS signaling fails during different externalization itiner-
aries. Together, these studies indicate that not all PS externalization
is phenotypically equivalent, and relevant to the thesis developed
in this perspective, whether the Xkr8/TMEM16F/ATP11c circuit
is compromised or genetically linked to SLE or other human auto-
immune disorders is an important and timely question in the
field.
OXIDATIVELY MODIFIED PS MAY PROVIDE AN ASSURANCE
SIGNAL FOR EFFEROCYTOSIS
The aforementioned discussion between the PS externalization
mechanisms of TMEM16F and Xkr8 is instructive, and highlights
the fact that PS externalization, per se, is not sufficient for efferocy-
tosis. Efferocytosis therefore must require an additional assurance
signal, affirming that the cell has passed a caspase-dependent
checkpoint and is ready to be engulfed and processed for degra-
dation (84, 85). Although it is likely that other plasma membrane
markers act in concert with externalized PS on apoptotic cell, one
idea that has gained traction in recent years is that oxPS, generated
in a caspase-dependent manner, provides a death-specific marker
for PS receptors, marking cells for engulfment (86). oxPS might be
expected to change the distribution of PS in the plasma membrane
rendering the cell more palatable, or conversely, PS oxidation could
serve as a better substrate for PS receptors (i.e., the “altered self”
idea) (2).
Although both ideas appear plausible, in support of the latter,
it has long been realized that antibodies specific to oxidized phos-
pholipids can block macrophage efferocytosis (87). Moreover, in
macrophages, the recognition of apoptotic cells via the scavenger
receptor CD36 occurs almost exclusively through interactions with
oxPS, and to a lesser extent oxidized PC (oxPC), but not non-oxPS.
Interestingly, the specificity of CD36 to oxPS within the apoptotic
membranes appears to be mediated by a structurally conserved
recognition motif for CD36 that comprises a “sn-2 acyl group
with a terminal γ-hydroxy (or oxo)-α, β-unsaturated carbonyl”
whereas, the reduction of this acyl chain prevents the oxPS/CD36
receptor activation (88). Other scavenger receptors implicated in
apoptotic cell clearance that includes; SRB1, SRA, LOX-1, CD68,
and CD14 (2, 89) also appear to selectively recognize the oxidized
sn-2 acyl group, suggesting this may be a conserved and universal
epitope in the apoptotic program.
In addition to scavenger receptors, recent studies also show
that some of the conventional PS-binding proteins and recep-
tors, such as GAS-6 and BAI-1, preferentially interact with oxPS,
although in the same study, it was also shown that non-oxPS pref-
erentially bound CXCL16 and Tim-4 (90), suggesting variations
on this theme. Although previous studies showed that the per-
oxidase function of caspase 3 could directly oxidize PS, PS can
be oxidized during inflammation as a result of enhanced lipid
peroxidation (88). The fact that various oxPS species may alter
the repertoire and/or change the affinities of PS toward scav-
enger receptors and PS receptors provides an impetus to better
understand the molecular basis of PS oxidation.
It is also noteworthy that oxysterols and oxPS can also indirectly
impinge on efferocytosis. For example, the engulfment of apop-
totic cells brings in large amounts of cellular lipids, including the
oxidized lipids alluded to above, into the intracellular compart-
ments of the phagocyte. Elegant studies have shown that these
internalized lipids can activate PPAR-δ receptors (91) and the
nuclear receptor LXR in macrophages (69), to induce engulfment
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receptors such as Mer and C1q. In mice, genetic ablation of PPAR-
δ results in impaired apoptotic cell clearance and SLE-like disease
(92), although the significance to human lupus still remains to be
determined.
LYSO-PS, A UNIQUE FORM OF PS, BINDS DISTINCT
RECEPTORS AND IS INVOLVED IN THE CLEARANCE OF
NON-APOPTOTIC NEUTROPHILS
Finally, in addition to (i) the modes of externalization, (ii) whether
PS is covalently oxidized, and (iii) whether a PS receptor is avail-
able to bind exposed PS on the surface of the apoptotic cell, under
certain circumstances PS can also be hydrolyzed under oxida-
tive conditions by a PS-specific phospholipase (PS-PLA1) (93–95)
to generate lyso-PS, a deacylated form of PS that serves as an
endogenous anti-inflammatory mediator. Although lyso-PS can
stimulate efferocytosis under certain conditions (96), this form
of PS remarkably also stimulates the uptake of live cells, and
has been implicated in the clearance of activated and aged live
neutrophils in anticipation for the resolution of inflammation.
Despite that PS and lyso-PS have the same anionic head group,
lyso-PS does not bind conventional PS receptors such as TAMs and
TIMs, but instead interacts with two G-protein coupled receptors,
GPR34 and G2A (97), which are linked to novel anti-inflammatory
molecules such as PGE2.
LESSONS FROM BLOCKING PS IN CANCER MODELS
In recent years, the idea that PS serves as a tolerogenic and global
immunosuppressive checkpoint has been therapeutically exploited
by the generation of anti-PS antibodies for cancer immunother-
apy. These studies show that systemic treatment of Bavitux-
imab (which recognizes a complex of β2-glycoprotein and PS),
can activate immune checkpoints, and drive the polarization of
macrophages from M2 to M1 and the activation of immature DCs
to antigen presenting cells, while decreasing MDSCs and Tregs in
tumor-bearing mice (98). As such, this pre-clinical finding has an
unanticipated consequence to ask whether blocking PS is sufficient
to induce autoimmunity. While the answers are not completely
clear, the available pre-clinical and clinical biosafety studies using
acute rather than chronic dosing regiments of Bavituximab (anti-
PS antibodies), suggest that anti-PS antibodies are well tolerated
and do not produce systemic autoimmunity or pulmonary throm-
bosis (99). Furthermore, vaccinating mice with apoptotic RMA
lymphoma cells pre-treated with Annexin-V attenuated the ability
of mice to reject a challenge with live RMA lymphoma cells (100).
Whether systemic anti-PS treatment exacerbates auto-immune
responses in lupus-prone individuals, or in individuals with anti-
phospholipid antibody (syndrome), has not been investigated.
It will be of interest to identify if patients that develop anti-
PS antibodies in SLE might have naturally occurring decreased
metastatic burden. Together, these data suggest that blockage of
PS, per se, may not be causal for the development of lupus, but
nonetheless re-activates specific arms of the immune response,
which may be fortuitously exploited where immunosuppressive
mechanisms operate within the tumor microenvironment. Future
studies, in mice, should be aimed to test whether anti-PS anti-
bodies augment lupus-like autoimmunity in genetic strains with a
propensity toward disease progression, and conversely whether PS
liposomes might also have unexpected therapeutic value. Finally,
several enveloped viruses such as Dengue, HIV, and Ebola virus
employ apoptotic (PS) mimicry to gain entry to host cells, and
blocking PS may also offer therapeutic prospects to block viral
entry and immune suppression (101–104).
CONCLUDING REMARKS
While the link between defective efferocytosis and auto-immune
disease and advanced atherosclerosis has been made, and validated
in experimental animal models, where and when this circuitry fails
in human disease has not been firmly established by genetic cau-
sation studies. In recent years, new developments have emerged
concerning the mechanisms of PS externalization, and the once
seemingly simple paradigm that externalized PS provides a signal
for efferocytosis and actively drives a resolution in acute inflam-
mation has been refined by the fact that externalized PS can exist in
different functional states. A challenging problem in the field will
be to decode the different biological fates of externalized PS, and
whether its ability to actively transmit signals is compromised in
human autoimmunity. Once the specific conditions can be identi-
fied, how exactly PS negatively impinges on chronic inflammation
can be elucidated further. These data would be helpful to under-
stand what components of the PS pathways fail during chronic
inflammation and autoimmunity.
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